Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study-Reference-Cited by-同舟云学术

Safety and effectiveness of neoadjuvant luteinizing hormone-releasing hormone agonist plus low-dose estramustine phosphate in high-risk prostate cancer: a prospective single-arm study

Published:2012-08-14 Issue:4 Volume:15 Page:397-401
ISSN:1365-7852
Container-title:Prostate Cancer and Prostatic Diseases
language:en
Short-container-title:Prostate Cancer Prostatic Dis

Author:

Koie T,Ohyama C,Yamamoto H,Hatakeyama S,Yoneyama T,Hashimoto Y,Kamimura N

Publisher

Springer Science and Business Media LLC

Subject

Cancer Research,Urology,Oncology

Link

http://www.nature.com/articles/pcan201229.pdf

Reference32 articles.

1. D’Amico AV, Whittington R, Malkowics SB, Schultz D, Blank K, Broderick GA et al. Biochemical outcomes after radical prostatectomy, external beam radiation therapy, or interstitial radiation therapy for clinically localized prostate cancer. JAMA 1998; 280: 969–974.

2. Joniau S, Van Poppel V . Localized prostate cancer: can we better define who is at risk of unfavorable outcome? BJU Int 2008; 101: S5–S10.

3. Soloway MS, Pareek K, Sharifi R, Wajsman Z, McLeod D, Wood Jr DP et al. Neoadjuvant androgen ablation before radical prostatectomy in cT2bNxM0 prostate cancer: 5-year results. J Urol 2002; 167: 112–116.

4. Gleave ME, Goldenberg SL, Chin JL, Warner J, Saad F, Klotz LH et al. Randomized comparative study of 3 versus 8-months neoadjuvant hormonal therapy before radical prostatectomy: biochemical and pathological effects. J Urol 2001; 166: 500–507.

5. Klotz LH, Goldenberg SL, Jewett MA, Fradet Y, Nam R, Barkin J et al. Long-term follow-up of a randomized trial of 0 versus 3 months of neoadjuvant androgen ablation before radical prostatectomy. J Urol 2003; 170: 791–794.

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Dose compliance of estramustine phosphate in neoadjuvant chemohormonal therapy combined with degarelix acetate predicts the biochemical recurrence in patients with very high‐risk prostate cancer who underwent robot‐assisted radical prostatectomy;International Journal of Urology;2024-09-10

2. Significance of pelvic lymph node dissection during radical prostatectomy in high-risk prostate cancer patients receiving neoadjuvant chemohormonal therapy;Scientific Reports;2022-06-11

3. Neoadjuvant Systemic Therapy Prior to Radical Prostatectomy for Clinically Localized High-Risk Prostate Cancer;Frontiers in Urology;2022-03-10

4. A review of clinical evidence to assess differences in efficacy and safety of luteinizing hormone–releasing hormone (LHRH) agonist (goserelin) and LHRH antagonist (degarelix);Indian Journal of Cancer;2022

5. Neoadjuvant hormonal therapy before radical prostatectomy in high-risk prostate cancer;Nature Reviews Urology;2021-09-15